LabPON Achieves 100 Percent Digital Diagnosis for Clinical Cases with Philips

Philips Royal Philips (NYSE: PHG, AEX: PHIA) announced that the Netherlands-based LabPON has become the first clinical pathology laboratory in the world to have transitioned completely to digital diagnosis. With this shift, all clinical histology cases are now being assessed and diagnosed digitally with the Philips IntelliSite Pathology Solution instead of with a microscope, leading to improved laboratory efficiency, quality and service levels.

Pathology plays a critical role in disease detection, particularly with cancer diagnosis. Suspicious tissue samples are investigated through a microscope to determine if the tissue is malignant and consequently guides treatment decisions. As the largest pathology laboratory in the Netherlands, LabPON is consulted on more than 54,000 histological cases each year, which translates to more than 300,000 slides of human tissue. Each of these slides needs to be prepared, analyzed, diagnosed, reported and archived every year. Digitizing these images eases collaboration across sites, reducing costs. Improved cooperation also allows access to specialists, engendering multidisciplinary discussions to share expertise and knowledge to ultimately come to a better diagnosis for the patient.

"Transitioning our entire workflow to digital processes demonstrates our commitment to ensuring our patients and clinical colleagues receive the fastest, most effective and best informed diagnoses possible," said Alexi Baidoshvili, pathologist, LabPON. "The revolutionary pathology solution from Philips provides us the images and speed we need, and their IT product seamlessly integrates with existing lab systems, while improving collaboration. Philips' understanding of the needs of our pathologists has ensured their adoption and improved throughput."

"Digitization of pathology offers a new way to tackle some of the growing challenges in the field, like higher cancer rates and the massive quantity of slides generated annually at these sites," said Russell Granzow, General Manager, Philips Digital Pathology Solutions. "LabPON's success in moving to entirely digital workflows emphasizes the role our solutions are playing across the health continuum to enable definitive diagnosis and improved patient care."

LabPON, which has 17 pathologists and a total of 115 employees, is also partnering with two other major labs in the Netherlands - University Medical Center Groningen and Isala Klinieken in Zwolle - to form a virtual network that allows 49 pathologists to collaborate easily, share cases in a secured way, and directly set up consultations.

LabPON has been working toward this milestone with Philips since 2012, using a structured change management approach to full digital adoption by its pathologists. This makes LabPON and Philips a valuable resource seeking to help others in their digital transformation.

Philips is an innovator in health technologies to enhance patient care and cure from healthy living and prevention, to diagnosis, treatment and home care. The company is a pioneer and leader in digital pathology, with a fast growing installed base and innovation partnerships with leading healthcare providers across the globe.

Philips IntelliSite Pathology Solution is a new platform to help pathologists make that next step in workflow improvement and accelerate knowledge sharing between care providers. Digital pathology will open up new ways to get more information from tissue samples and connect with other diagnostic modalities. Philips IntelliSite Pathology Solution is CE marked for primary diagnostics in the EU and Health Canada. In the U.S., Philips IntelliSite Pathology Solution is cleared by FDA for diagnostic use in the evaluation of HER2 expression in breast cancer and is offered for research use (RUO).

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About LabPON
LabPON represents Laboratory Pathology East Netherlands and is located in in Hengelo, The Netherlands. LabPON carries out pathological examinations for hospitals and general practices in the region Twente and Achterhoek- East. As the largest pathology laboratory in the Netherlands, it is committed to excel in speed and quality to the benefit of each patient. The development of digital pathology will certainly contribute to this.

Most Popular Now

Stanford Medicine Study Suggests Physici…

Artificial intelligence-powered chatbots are getting pretty good at diagnosing some diseases, even when they are complex. But how do chatbots do when guiding treatment and care after the diagnosis? For...

OmicsFootPrint: Mayo Clinic's AI To…

Mayo Clinic researchers have pioneered an artificial intelligence (AI) tool, called OmicsFootPrint, that helps convert vast amounts of complex biological data into two-dimensional circular images. The details of the tool...

Testing AI with AI: Ensuring Effective A…

Using a pioneering artificial intelligence platform, Flinders University researchers have assessed whether a cardiac AI tool recently trialled in South Australian hospitals actually has the potential to assist doctors and...

Adults don't Trust Health Care to U…

A study finds that 65.8% of adults surveyed had low trust in their health care system to use artificial intelligence responsibly and 57.7% had low trust in their health care...

AI Unlocks Genetic Clues to Personalize …

A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes - insights that could help doctors tailor...

The 10 Year Health Plan: What do We Need…

Opinion Article by Piyush Mahapatra, Consultant Orthopaedic Surgeon and Chief Innovation Officer at Open Medical. There is a new ten-year plan for the NHS. It will "focus efforts on preventing, as...

Deep Learning to Increase Accessibility…

Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor heart disease, myocardial perfusion imaging (MPI) by single photon...

People's Trust in AI Systems to Mak…

Psychologists warn that AI's perceived lack of human experience and genuine understanding may limit its acceptance to make higher-stakes moral decisions. Artificial moral advisors (AMAs) are systems based on artificial...

DMEA 2025 - Innovations, Insights and Ne…

8 - 10 April 2025, Berlin, Germany. Less than 50 days to go before DMEA 2025 opens its doors: Europe's leading event for digital health will once again bring together experts...

Relationship Between Sleep and Nutrition…

Diet and sleep, which are essential for human survival, are interrelated. However, recently, various services and mobile applications have been introduced for the self-management of health, allowing users to record...

New AI Tool Mimics Radiologist Gaze to R…

Artificial intelligence (AI) can scan a chest X-ray and diagnose if an abnormality is fluid in the lungs, an enlarged heart or cancer. But being right is not enough, said...

AI Model can Read ECGs to Identify Femal…

A new AI model can flag female patients who are at higher risk of heart disease based on an electrocardiogram (ECG). The researchers say the algorithm, designed specifically for female patients...